% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Weller:284416,
      author       = {J. Weller and T. Zeyen and N. Schäfer and C. Schaub and
                      A.-L. Potthoff and J. P. Steinbach$^*$ and P. Hau and C.
                      Seidel and R. Goldbrunner and G. Tabatabai$^*$ and H. Vatter
                      and T. Tzaridis and M. Schneider and U. Herrlinger},
      title        = {{T}he proneural subtype is not associated with survival
                      benefit from bevacizumab in newly diagnosed glioblastoma: a
                      secondary analysis of the {GLARIUS} trial.},
      journal      = {Journal of neuro-oncology},
      volume       = {164},
      number       = {3},
      issn         = {0167-594X},
      address      = {Dordrecht [u.a.]},
      publisher    = {Springer Science + Business Media B.V},
      reportid     = {DKFZ-2023-02005},
      pages        = {749-755},
      year         = {2023},
      note         = {2023 Sep;164(3):749-755},
      abstract     = {The AVAglio trial reported a significant survival benefit
                      for first line bevacizumab treatment in patients with IDH
                      wildtype glioblastoma of the proneural gene expression
                      subtype. We here aim to replicate these findings in an
                      independent trial cohort.We evaluate the treatment benefit
                      of bevacizumab according to gene expression subtypes of
                      pretreatment tumor samples (n = 123) in the GLARIUS trial
                      (NCT00967330) for MGMT unmethylated glioblastoma patients
                      with Kaplan-Meier analyses, log-rank tests and Cox
                      regression models.Employing the Phillips classifier,
                      bevacizumab conferred a significant PFS advantage in
                      patients with proneural IDH wild-type tumors (10.4 vs. 6.0
                      months, p = 0.002), but no OS advantage (16.4 vs. 17.4
                      months, p = 0.6). Multivariable analysis adjusting for
                      prognostic covariates confirmed the absence of a significant
                      OS advantage from bevacizumab (hazard ratio, 1.05, $95\%$
                      CI, 0.42 to 2.64; p = 0.14). Further, there was no
                      interaction between the proneural subtype and treatment arm
                      (p = 0.15). These results were confirmed in analyses of
                      tumor subgroups according to the Verhaak classifier.In
                      contrast to AVAglio, glioblastoma gene expression subgroups
                      were not associated with a differential OS benefit from
                      first-line bevacizumab in the GLARIUS trial.},
      keywords     = {Bevacizumab (Other) / Gene expression (Other) /
                      Glioblastoma (Other) / Newly diagnosed glioblastoma (Other)},
      cin          = {FM01 / TU01},
      ddc          = {610},
      cid          = {I:(DE-He78)FM01-20160331 / I:(DE-He78)TU01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37787906},
      doi          = {10.1007/s11060-023-04470-9},
      url          = {https://inrepo02.dkfz.de/record/284416},
}